GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Kras | multiple interactions | EXP | | 6480464 | CTD | [cumene co-treated with KRAS gene mutant form] results in decreased expression of CCN1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of CEBPD mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of CKS1B mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of DLC1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of DUSP14 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of DUSP3 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of ENO1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of ENPP2 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of EPCAM mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of GPER1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of IGFBP4 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of KRT18 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of KRT8 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of LASP1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of MMP14 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of RACK1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of RB1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of SDC1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of SLC2A1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of SOD3 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of SRD5A1 mRNA; [cumene co-treated with KRAS gene mutant form] results in decreased expression of VWF mRNA; [cumene co-treated with KRAS gene mutant form] results in increased expression of AREG mRNA; [cumene co-treated with KRAS gene mutant form] results in increased expression of CCND1 mRNA; [cumene co-treated with KRAS gene mutant form] results in increased expression of EREG mRNA; [cumene co-treated with KRAS gene mutant form] results in increased expression of KLF5 mRNA; [cumene co-treated with KRAS gene mutant form] results in increased expression of LAMTOR2 mRNA; [cumene co-treated with KRAS gene mutant form] results in increased expression of MAP2K1 mRNA; [cumene co-treated with KRAS gene mutant form] results in increased expression of MAP2K1 protein; [cumene co-treated with KRAS gene mutant form] results in increased expression of MIF mRNA; [cumene co-treated with KRAS gene mutant form] results in increased expression of PTGES mRNA; KRAS gene mutant form promotes the reaction [cumene results in increased expression of CLU mRNA] | PMID:18648096 | |
Go Back to source page | Continue to Ontology report |